Zoetis Inc. (0M3Q.L)
USD 147.42
(-3.98%)
USD 147.42
(-3.98%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.28 Billion USD | -4.28% |
| 2022 | 14.92 Billion USD | 7.37% |
| 2021 | 13.9 Billion USD | 2.14% |
| 2020 | 13.6 Billion USD | 17.88% |
| 2019 | 11.54 Billion USD | 7.13% |
| 2018 | 10.77 Billion USD | 25.52% |
| 2017 | 8.58 Billion USD | 12.25% |
| 2016 | 7.64 Billion USD | -3.34% |
| 2015 | 7.91 Billion USD | 19.77% |
| 2014 | 6.6 Billion USD | 0.75% |
| 2013 | 6.55 Billion USD | 4.73% |
| 2012 | 6.26 Billion USD | 9.65% |
| 2011 | 5.71 Billion USD | 8.08% |
| 2010 | 5.28 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 14.35 Billion USD | 1.36% |
| 2024 Q2 | 14.16 Billion USD | -1.28% |
| 2024 Q1 | 14.34 Billion USD | 0.43% |
| 2023 Q4 | 14.28 Billion USD | 1.28% |
| 2023 FY | 14.28 Billion USD | -4.28% |
| 2023 Q2 | 13.74 Billion USD | -0.04% |
| 2023 Q3 | 14.1 Billion USD | 2.6% |
| 2023 Q1 | 13.75 Billion USD | -7.85% |
| 2022 Q4 | 14.92 Billion USD | 9.15% |
| 2022 FY | 14.92 Billion USD | 7.37% |
| 2022 Q2 | 13.77 Billion USD | -0.65% |
| 2022 Q1 | 13.86 Billion USD | -0.29% |
| 2022 Q3 | 13.67 Billion USD | -0.7% |
| 2021 Q2 | 14.06 Billion USD | 1.98% |
| 2021 Q3 | 13.7 Billion USD | -2.59% |
| 2021 FY | 13.9 Billion USD | 2.14% |
| 2021 Q1 | 13.79 Billion USD | 1.37% |
| 2021 Q4 | 13.9 Billion USD | 1.42% |
| 2020 Q4 | 13.6 Billion USD | -0.85% |
| 2020 FY | 13.6 Billion USD | 17.88% |
| 2020 Q1 | 11.52 Billion USD | -0.15% |
| 2020 Q2 | 13.06 Billion USD | 13.37% |
| 2020 Q3 | 13.72 Billion USD | 5.02% |
| 2019 Q4 | 11.54 Billion USD | 2.42% |
| 2019 Q1 | 10.88 Billion USD | 0.98% |
| 2019 Q2 | 10.98 Billion USD | 0.95% |
| 2019 Q3 | 11.27 Billion USD | 2.6% |
| 2019 FY | 11.54 Billion USD | 7.13% |
| 2018 Q4 | 10.77 Billion USD | 3.04% |
| 2018 FY | 10.77 Billion USD | 25.52% |
| 2018 Q3 | 10.45 Billion USD | 21.57% |
| 2018 Q2 | 8.6 Billion USD | -1.0% |
| 2018 Q1 | 8.69 Billion USD | 1.21% |
| 2017 Q3 | 9.28 Billion USD | 19.05% |
| 2017 FY | 8.58 Billion USD | 12.25% |
| 2017 Q2 | 7.8 Billion USD | 2.0% |
| 2017 Q1 | 7.64 Billion USD | 0.0% |
| 2017 Q4 | 8.58 Billion USD | -7.56% |
| 2016 FY | 7.64 Billion USD | -3.34% |
| 2016 Q1 | 7.45 Billion USD | -5.81% |
| 2016 Q3 | 7.71 Billion USD | 2.62% |
| 2016 Q2 | 7.51 Billion USD | 0.87% |
| 2016 Q4 | 7.64 Billion USD | -0.86% |
| 2015 FY | 7.91 Billion USD | 19.77% |
| 2015 Q2 | 6.59 Billion USD | 2.61% |
| 2015 Q4 | 7.91 Billion USD | 18.35% |
| 2015 Q3 | 6.68 Billion USD | 1.33% |
| 2015 Q1 | 6.43 Billion USD | -2.68% |
| 2014 Q1 | 6.4 Billion USD | -2.36% |
| 2014 Q2 | 6.52 Billion USD | 1.86% |
| 2014 Q3 | 6.52 Billion USD | 0.08% |
| 2014 Q4 | 6.6 Billion USD | 1.23% |
| 2014 FY | 6.6 Billion USD | 0.75% |
| 2013 FY | 6.55 Billion USD | 4.73% |
| 2013 Q1 | 6.14 Billion USD | -1.92% |
| 2013 Q2 | 6.26 Billion USD | 1.94% |
| 2013 Q3 | 6.25 Billion USD | -0.03% |
| 2013 Q4 | 6.55 Billion USD | 4.78% |
| 2012 Q4 | 6.26 Billion USD | 6.06% |
| 2012 Q2 | 5.8 Billion USD | -1.79% |
| 2012 Q3 | 5.9 Billion USD | 1.79% |
| 2012 FY | 6.26 Billion USD | 9.65% |
| 2012 Q1 | 5.9 Billion USD | 3.41% |
| 2011 FY | 5.71 Billion USD | 8.08% |
| 2011 Q4 | 5.71 Billion USD | 0.0% |
| 2010 FY | 5.28 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -1617.709% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -1424.461% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -1736.53% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -8531.816% |
| bluebird bio, Inc. | 619.16 Million USD | -2207.316% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -11252.15% |
| Imunon, Inc. | 21.91 Million USD | -65079.099% |
| Editas Medicine, Inc. | 499.15 Million USD | -2762.048% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 46.456% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -325.742% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -1091.791% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -339.38% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -913.927% |
| Verastem, Inc. | 149.71 Million USD | -9441.939% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 82.371% |
| Waters Corporation | 4.62 Billion USD | -208.763% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 85.53% |
| Biogen Inc. | 26.84 Billion USD | 46.783% |
| Nektar Therapeutics | 398.03 Million USD | -3489.15% |
| Perrigo Company plc | 10.8 Billion USD | -32.166% |
| Dynavax Technologies Corporation | 997.09 Million USD | -1332.761% |
| Illumina, Inc. | 10.11 Billion USD | -41.292% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -50429.858% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -1730.715% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -6320.501% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -21647.602% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -108.811% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -8541.423% |
| Evolus, Inc. | 188.99 Million USD | -7458.81% |
| Adicet Bio, Inc. | 207.29 Million USD | -6791.628% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -7136.899% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 56.814% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -6841.826% |
| FibroGen, Inc. | 423.52 Million USD | -3273.087% |
| Agilent Technologies, Inc. | 10.76 Billion USD | -32.733% |
| OPKO Health, Inc. | 2.01 Billion USD | -610.146% |
| Homology Medicines, Inc. | 47.05 Million USD | -30258.926% |
| Geron Corporation | 394.07 Million USD | -3525.189% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -273.014% |
| Exelixis, Inc. | 2.94 Billion USD | -385.529% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -3776.903% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -9153.43% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -998.098% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -2328.617% |
| Abeona Therapeutics Inc. | 64 Million USD | -22221.178% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 37.15% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -25433.968% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -377.781% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -337.607% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -2198.569% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -724.222% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -1261.544% |
| Insmed Incorporated | 1.32 Billion USD | -974.267% |
| TG Therapeutics, Inc. | 329.58 Million USD | -4234.516% |
| Incyte Corporation | 6.78 Billion USD | -110.643% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -678.571% |